NEWS
Quotient Sciences Announces Multimillion-Pound Investment in Drug Substance Manufacturing Facility
Read article
Isotope Labelling
Secure & rapid delivery of isotopically labelled (14C/SIL) materials for non-clinical & clinical human studies.
With over 30 years of successful delivery on-site, Quotient Sciences' highly trained chemists have extensive chemical and radiochemical knowledge and the experience required to supply consultancy and advice on the most suitable labelling positions for a variety of molecular entities.
Isotope Labelling Services Include:
•GMP & non GMP synthesis
•14C radiolabelling
•Ability to handle highly potent/high hazard compounds (cytotoxics)
•Synthesis of metabolites & reference standards aiding bioanalytical and metabolism studies
•Degradants and process impurities to support API development
•Route development and precursor synthesis for labelling with 3H and short-lived isotopes 11C and 18F
•Classical and non-classical synthetic techniques
•Flow chemistry
•Automated peptide synthesis capability
•Microbiological and bio-catalysis
•Stable isotope label (SIL) synthesis, including 2H, 13C, 15N & 18O
Isotope Labelling Resources
-
Info SheetIsotope LabellingWhether you need isotopically labelled (14C/SIL) compounds for nonclinical or clinical metabolism studies and the quantification of materials in biological matrices, our expertise provides the necessary labelled materials tailored to support your studies.
-
Case StudiesStable Isotope Labelling Case StudyMultiple, biotechnology and large-pharma companies needing isotope labelling support for their ADME/hAME studies
-
Scientific PostersEuPFI 2021 - Taste Assessment Study of Belumosudil to Inform an Integrated Paediatric Formulation Development ProgramPresentied at the annual EuPFI event, this poster dicuments the project of Belumosudil, a ROCK2 selective inhibitor, is currently in development for the treatment of immune disorders.
-
WebinarCandidate Selection WebinarJoin Us for our Candidate Selection Webinar on November 17, 2021. This webinar explains the benefits of adopting a holistic approach at the candidate selection-development interface. The tight integration of the drug substance, biopharmaceutics and drug product activities, encourages cross-functional workflows enabling chemists to talk to formulators and DMPK scientists to talk to clinicians, for example.
Ready to get started?
Connect With Quotient Today
We use cookies to help us to improve our site and enables us to the best possible service and customer experience. By clicking accept you are agreeing to let us share your data with select third parties for analytics and marketing purposes.